General Introduction
Fig. 1.1 Disease course patterns in MS: (a) Relapsing and Remitting MS (RRMS): clearly defined acute attacks with recovery. (b) Primary Progressive MS (PPMS): progression of disability from onset without…
Clinical Use of OCT and MSON Mimics
Differential diagnosis Clinical features MSON Mostly good recovery within 2 months ION Isolated ON RION Isolated ON with spontaneous relapses CRION Relapses on steroid withdrawal, poor recovery NMO-ON Relapses, poor…
Optical Coherence Tomography (OCT)
Fig. 3.1 The setup should allow for good OCT examination conditions. Patients may require wheelchair access and additional help during the assessment for which there needs to be sufficient space….
OCT in Relapsing–Remitting Multiple Sclerosis (RRMS)
Fig. 8.1 Panel (a) represents a fundus photograph from a healthy control. Panel (b) is a 3D macular volume cube generated by Cirrus HD-OCT from the macular region denoted by…
Retrograde Maculopathy
Fig. 10.1 Typical example of a microcystic macular edema (MME) in a patient with a compressive optic neuropathy. Thickness maps of ganglion cell layer (GCL) and inner nuclear layer (INL)…
MS-Associated Optic Neuritis (MSON)
Disease-free controls All MS MS, no history of MSON MS, history of MSON High-contrast visual acuity (VA), ETDRS, number of letters correct 59 ± 6 (n = 52 eyes) 53 ± 10 (n = 559 eyes) 55 ± 7…
Progressive Multiple Sclerosis (SP and PP MS)
Fig. 9.1 Progressive multiple sclerosis nomenclature. Progressive MS nomenclature according to the current criteria [2] Prior to the 2013 MS disease course revision, the phenotype of a patient with primary…
Role of the OCT Reading Center
Fig. 13.1 Flowchart showing the three major phases of a study and the involvement of the RC in each of these phases During the execution phase, the RC supports several…
Drug Trials in Neuroprotection
Trial (phase) Goal Drug Indication Primary outcome Secondary outcomes Alpha error Power Effect size Sample per arm Status Ref/NCT ACTION (RCT Phase II) Primary neuroprotection I: Amiloride C: Placebo iAON…
OCT Findings in Neuromyelitis Optica Spectrum Disorders
Fig. 6.1 Peripapillary and macular OCT scan from a healthy control (HC; female 30 years old), a multiple sclerosis associated optic neuritis eye (MSON eye; female 32 years old), and…
